Gene and Cell Therapy

The Most Comprehensive, State-of-the-Art Book on Using Gene and Cell Therapy in Clinical Medicine Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, Fifth Edition presents extensive background and basic information, state-of-the-art technologies, important achievements, and lingering challenges in the fields of gene and cell therapies. The fifth edition of this bestseller continues to provide the most comprehensive coverage of these fields in one volume. Some chapters have expanded introductions, making the book even more suitable for classroom use. This edition also offers more material on the contributors’ research efforts as well as current technologies, disease targets, and clinical applications.
Divided into four sections, the book covers:
Delivery systems and therapeutic strategies
Other therapeutic strategies, including technologies that knock down gene expression
Gene expression, regulation, and detection
Gene and cell therapies, disease targets, clinical trials, and regulatory issues

Accessible to a broad audience, including students, scientists, physicians, and lay people, this book provides readers with up-to-date, interdisciplinary knowledge and tools to tackle the evolving areas of gene therapy, cell therapy, and tissue engineering. From introductory information to state-of-the-art technologies and concepts, the book helps readers understand vector design and construction, delivery systems, therapeutic strategies, gene expression and detection, disease targets, clinical applications and trials, cell-based therapies, novel imaging systems, gene regulation, and regulatory affairs.

Dr. Graça Almeida-Porada earned her MD and her PhD from School of Medicine and Biomedical Sciences at the University of Porto, Portugal. She is currently a Professor and the Director of the Fetal Research and Therapy Program at the Wake Forest Institute for Regenerative Medicine. She is also a Professor in the Department of Internal Medicine, Section of Hematology and Oncology, and School of Biomedical Engineering and Sciences, Wake Forest School of Medicine.

Dr. Almeida-Porada’s research focuses on the development of cellular and gene delivery platforms to treat genetic and immune-mediated diseases. She is particularly interested in improving the outcome of stem cell transplantation and gene therapy in fetal and neonatal patients with genetic disorders, and in developing therapies for children with immune-mediated diseases.

She is the co-founder of the International Fetal Transplantation and Immunology Society, whose mission is to accelerate clinical applications of stem cell transplantation and gene therapy approaches to treat fetuses with congenital disorders.

Dr. Almeida-Porada serves on numerous review panels, study sections, and professional and scientific committees, and she is a reviewer for many peer-reviewed journals. She has been a member of several NIH study sections, and she serves as an Editor, or on the Editorial Boards, of multiple scientific journals and book series. Dr. Almeida-Porada also serves on the scientific advisory boards for several ongoing prenatal clinical trials, both in the US and in Europe.

Dr. Almeida-Porada holds several patents, and she has authored more than 300 scientific works including papers, abstracts, and book chapters.

Dr. Anthony Atala is a practicing surgeon and the G. Link Professor and Director of the Wake Forest Institute for Regenerative Medicine. His work focuses on bioprinting and growing human cells, tissues and organs. Seventeen applications of technologies developed in Dr. Atala's laboratory have been used clinically. Dr. Atala was elected to the National Academy of Medicine, the National Academy of Inventors, and the American Institute for Medical and Biological Engineering. He is a recipient of the US Congress funded Christopher Columbus Foundation Award, bestowed on a living American who is currently working on a discovery that will significantly affect society, the World Technology Award in Health and Medicine, the Edison Science/Medical Award, the R&D Innovator of the Year Award, and the Smithsonian Ingenuity Award. Dr. Atala’s work was listed twice as Time Magazine’s top 10 medical breakthroughs of the year, as one of 5 discoveries that will change the future of organ transplants and was ranked by the Project Management Institute as one of the top 10 most impactful biotech projects from the past 50 years. Dr. Atala was named by Scientific American as one of the world’s most influential people in biotechnology, by U.S. News & World Report as one of 14 Pioneers of Medical Progress in the 21st Century, by Life Sciences Intellectual Property Review as one of 50 key influencers in the life sciences intellectual property arena, and by the journal Nature Biotechnology as one of the top 10 translational researchers in the world. Dr. Atala has led or served several national professional and government committees, including the National Institutes of Health working group on Cells and Developmental Biology, the National Institutes of Health Bioengineering Consortium, and the National Cancer Institute’s Advisory Board. He was a Founder of the Tissue Engineering Society, the Regenerative Medicine Society, the Regenerative Medicine Foundation, the Alliance for Regenerative Medicine, the Regenerative Medicine Development Organization, the Regenerative Medicine Manufacturing Society, and the Regenerative Medicine Manufacturing Consortium. Dr. Atala is editor of 25 books and 2 journals, has published more than 900 journal articles, and has applied for or received over 300 national and international patents.